# OnCo record thomas-powles (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/thomas-powles/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "thomas-powles" ;
  schema:name "Thomas Powles"@en ;
  schema:description "Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care."@en ;
  schema:url <https://onco.cc/people/thomas-powles/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.bartscancer.london/>, <https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial> ;
  onco:tag "urothelial", "adc", "ctdna", "trialist" ;
  schema:jobTitle "Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London" ;
  schema:sameAs <https://orcid.org/0000-0001-7760-4724> ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/nectin4/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/enfortumab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/signatera/> ;
  onco:institutions <https://onco.cc/institutions/barts-cancer-institute/> ;
  onco:trials <https://onco.cc/trials/ev-302/>, <https://onco.cc/trials/niagara/>, <https://onco.cc/trials/javelin-bladder-100/>, <https://onco.cc/trials/imvigor011/>, <https://onco.cc/trials/keynote-426/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ev-302-nejm-2024/>, <https://onco.cc/key-papers/paper-niagara-nejm-2024/>, <https://onco.cc/key-papers/paper-imvigor011-nejm-2025/> ;
  schema:affiliation <https://onco.cc/institutions/barts-cancer-institute/> .